Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia
NCT ID: NCT00793520
Last Updated: 2010-07-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
2 participants
INTERVENTIONAL
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia
NCT01173055
Effect of Milnacipran on Pain in Fibromyalgia
NCT01288807
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia
NCT01077375
Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial
NCT01829243
Study of Milnacipran for the Treatment of Fibromyalgia
NCT00314249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Twice daily oral administration of milnacipran for 5 weeks, placebo for 2 weeks, and crossover to placebo for 5 weeks.
Milnacipran
Twice daily oral administration of Milnacipran for 5 weeks.
Placebo
Twice daily oral administration of placebo for 5 weeks.
2
Twice daily oral administration of placebo for 5 weeks, placebo for 2 weeks, and crossover to milnacipran for 5 weeks.
Placebo
Twice daily oral administration of placebo for 5 weeks.
Milnacipran
Twice daily oral administration of Milnacipran for 5 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Milnacipran
Twice daily oral administration of Milnacipran for 5 weeks.
Placebo
Twice daily oral administration of placebo for 5 weeks.
Placebo
Twice daily oral administration of placebo for 5 weeks.
Milnacipran
Twice daily oral administration of Milnacipran for 5 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Visual analog pain score between 40 and 90 mm
* Right-hand dominance
Exclusion Criteria
* Substance Abuse
* Pulmonary dysfunction
* Renal impairment
* Active cardiac disease
* Autoimmune disease
* Uncontrolled narrow-angle glaucoma
* Active liver disease
* Cancer
* Active peptic ulcer disease or a history of inflammatory bowel disease or celiac sprue
* Unstable endocrine disease
* Prostatic enlargement
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Forest Research Insititute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Allan Spera
Role: STUDY_DIRECTOR
Forest Research Institute, a subsidiary of Forest Laboratories Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Forest Investigative Site
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MLN-MD-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.